Related Experiment Video
Updated: Jun 2, 2026
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
Published on: January 9, 2019
Molecular markers in low-grade gliomas: predictive or prognostic?
Christian Hartmann1, Bettina Hentschel, Marcos Tatagiba
1Clinical Cooperation Unit Neuropathology, German Cancer Center & Department of Neuropathology, Institute of Pathology, Ruprecht-Karls University Heidelberg, Heidelberg, Germany. christian.hartmann@med.uni-heidelberg.de
Molecular markers like IDH1 mutations show promise for predicting survival in low-grade gliomas, especially when treated with chemotherapy or radiotherapy. However, these markers are not yet reliable for predicting outcomes in patients receiving only surgery.
Area of Science:
- Neuro-oncology
- Molecular diagnostics
- Cancer biomarkers
Background:
- Low-grade gliomas (WHO grade II) are heterogeneous tumors.
- Accurate prognostication is crucial for guiding treatment decisions.
- Identifying reliable biomarkers can improve patient outcomes.
Purpose of the Study:
- To evaluate TP53 mutation, 1p/19q codeletions, MGMT promoter methylation, and IDH1 mutation as predictors of disease course.
- To determine if these molecular markers predict response to radiotherapy or chemotherapy in low-grade glioma patients.
- To assess the prognostic value of these markers in different treatment settings.
Main Methods:
- Two cohorts of WHO grade II glioma patients were analyzed: Cohort A (surgery alone, n=89) and Cohort B (radiotherapy/chemotherapy, n=50).
- Tumor samples were tested for TP53 mutations, 1p/19q codeletions, MGMT promoter methylation, and IDH1 mutations.
- Progression-free survival (PFS) and overall survival (OS) were assessed in relation to molecular markers and treatment.
Main Results:
- No molecular marker was prognostic for PFS in patients treated with surgery alone (Cohort A).
- IDH1 mutations were associated with prolonged survival in oligoastrocytomas/oligodendrogliomas and overall survival across all tumors.
- 1p/19q codeletion and IDH1 mutation were prognostic for PFS and OS in patients receiving radiotherapy or chemotherapy (Cohort B).
Conclusions:
- The investigated molecular markers are not sensitive prognostic biomarkers for WHO grade II glioma patients undergoing surgery alone.
- IDH1 mutation status is the strongest prognostic marker for overall survival, irrespective of histology.
- Further research is needed to clarify treatment-specific effects due to study limitations such as sample size and non-randomized treatment allocation.
